Bracco Imaging announced that the Brazilian National Health Surveillance Agency (ANVISA) has approved its SonoVue ultrasound contrast agent.
The second-generation ultrasound contrast agent is indicated for use in echocardiography in patients with suspected or established cardiovascular disease, Doppler ultrasound of microvasculature to increase the accuracy in detection or exclusion of abnormalities in cerebral arteries, and Doppler ultrasound of microvasculature to improve the display of the vascularity of liver and breast lesions, according to Bracco.